A Study of 2 Doses of MAP0010 in Adult Asthmatics

Completed · Phase 2

Conditions studied: Asthma

In brief

The purpose of this study is to examine the blood levels of two doses of MAP0010 (a corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with twice daily dosing over 7 days.

Key facts

Study ID

NCT00554970

Run by

Allergan

People needed

32

Starts

2007-11-01

Expected to finish

2008-03-01

Last updated by the study team

2014-01-09

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female adult asthmatics with mild to moderate persistent asthma.
• 18 to 45 (up to the 46th birthday) years of age.
• Documented diagnosis of asthma at least 3 months prior to Visit 1, per NIH/NHLBI, EPR-3 criteria.
• Able to withhold short-acting bronchodilators (e.g., albuterol or ipratropium bromide) for at least 4 hours prior to clinic visits.
• Baseline FEV1 greater than or equal to 50% of predicted normal.

You may not qualify if…

• Any other significant illness/abnormality
• A history of upper or lower respiratory tract infection within 2 weeks
• A history of acute or severe asthma attack requiring ICU admission or ventilatory support.

Where it is running

• West Coast Clinical Trials Phase 2-4, LLC — Long Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.